Grant Accounting for Life Sciences: Building Financial Infrastructure for Non-Dilutive Funding

Grant funding is among the most efficient capital a life sciences company can raise. It extends runway, advances research programs, and signals external validation of the science, all without diluting ownership. The value of that capital is realized through the financial systems that manage it. Grant funding arrives with spending conditions and reporting expectations that reward disciplined accounting, and a company that treats grant accounting as core financial infrastructure protects the funding it has won while positioning itself to manage more.

For finance leaders at early-stage and growth-stage life sciences companies, the work comes down to a handful of accounting processes built early and applied consistently. The sections below cover the ones that carry the most weight.

Why Grant Accounting Is Different

Investor capital and grant funding serve different purposes and behave differently on the financial statements. Equity investment arrives as cash on the balance sheet in exchange for ownership and is available for general use. Grant funding is typically earned against specific, allowable costs and released on a reimbursement or milestone basis, which makes it function more like a performance-based arrangement than a lump-sum infusion.

That difference drives distinct processes: revenue recognized as costs are incurred, receivables tracked between spending and reimbursement, expenses tied to specific programs, and documentation maintained to support every dollar claimed. The administrative structure is the price of non-dilutive capital, and companies that build it deliberately turn it into an advantage. A strong financial planning foundation makes that structure far easier to establish.

Recognize Grant Revenue Correctly

Most research grants are structured so the company earns revenue as it incurs allowable costs rather than when cash arrives. Funders typically reimburse on a cycle that lags actual spending, so the income statement and the cash position move on different timelines. Two disciplines keep the picture accurate: record a receivable when allowable costs run ahead of reimbursement, and hold advance payments in deferred revenue until the related work is performed.

Matching recognized revenue to the costs that earned it keeps margins and program performance legible to the board and to anyone conducting diligence. For life sciences companies funding research programs, this matching is one of the most common places early-stage reporting drifts, and it is also one of the most straightforward to get right with a defined process in place from the start.

Track Costs by Project and Funding Source

A life sciences company often runs several research programs at once, each supported by a different funding source with its own budget and reporting needs. Clear visibility into which expenses belong to which program is the foundation of credible grant accounting. That visibility comes from a chart of accounts with project or program dimensions, so direct costs such as scientific salaries, lab supplies, and subcontractor fees attach to the right program from the moment they are incurred.

Reconstructing that mapping after the fact is slow and error-prone, and it weakens the company's ability to report accurately to each funder. The cost accounting practices that suit life sciences R&D are built around this kind of program-level visibility. That same visibility serves leadership directly, showing which programs consume capital most efficiently and how funding is translating into scientific progress, which sharpens decisions about where to commit resources next.

Allocate Shared Costs Consistently

Some costs support several programs at once: facilities, administration, shared equipment, and the finance function itself. These shared costs need an allocation methodology that is documented, reasonable, and applied the same way across periods and programs. The specific basis a company chooses matters less than the consistency and the documentation behind it.

A method the company can explain and support holds up when a funder or an acquirer looks closely. An approach that shifts to flatter a particular program or period invites questions about the rest of the numbers. Setting the methodology early and applying it consistently keeps shared-cost allocation from becoming a recurring source of friction as the company grows.

Build Documentation Before You Need It

Documentation is most valuable when it is created in real time, well ahead of any review. In practice that means project codes that isolate program spending, labor and effort records that show how people's time maps to programs, supporting detail behind shared-cost allocations, and basic financial controls over how costs are approved and recorded.

Building these records as funding arrives makes audit readiness a byproduct of normal operations rather than a year-end scramble. The same records that satisfy a reviewer also give the finance team faster, cleaner reporting throughout the year, which compounds as the number of active programs grows.

How Strong Grant Accounting Supports Growth

Grant accounting done well compounds over time. Clean, program-level records shorten diligence when the company raises equity or enters a partnership, because investors and acquirers can trace funding to results without friction. A company moving toward life sciences diligence readiness benefits directly from records that were maintained well before the transaction appeared on the horizon.

Disciplined cost tracking also makes it practical to add new funding sources without overwhelming the finance function, since the structure already exists to absorb them. As the portfolio of programs and funders grows, that scalability becomes a real advantage, and a finance team with life sciences experience tends to provide more reliable coverage than a generalist hired into the role.

Grant Funding Creates Complexity Before It Creates Scale

Many life sciences companies receive grant funding before they have a fully built finance function, which means accounting complexity often arrives ahead of organizational scale. A company juggling multiple grants, research programs, and reporting requirements can quickly outgrow spreadsheets and informal processes. Financial infrastructure becomes more important as non-dilutive funding grows, and the companies that recognize that early tend to add programs and funders without the finance function becoming a bottleneck.

Turn Non-Dilutive Funding Into a Financial Advantage

Non-dilutive funding rewards the companies that manage it with discipline. A well-built accounting function converts grant capital into a durable advantage: revenue recognized accurately, costs tracked to the right programs, shared costs allocated consistently, and documentation ready whenever it is needed. The structure that supports all of this is financial infrastructure, and it is most effective when it is built before the company is under pressure to produce it.

G-Squared Partners works with life sciences and biotech companies to build the financial infrastructure that grant-funded growth requires, from revenue recognition and project-level cost tracking to documentation, reporting, and managing multiple funding sources at once. Our outsourced CFO and accounting team for life sciences pairs day-to-day accounting rigor with the strategic perspective a finance leader needs to put that capital to work.

If your company is managing grant funding or preparing for its next phase of growth, schedule a free consultation to talk through your financial operations.